The Gaucher and Pompe diseases enzyme replacement therapy (ERT) market has seen remarkable evolution over the years. Driven by advancements in biotechnology, increasing awareness of rare genetic disorders, and enhanced diagnostic capabilities, the demand for enzyme replacement therapy continues to rise. Both Gaucher disease and Pompe disease are inherited lysosomal storage disorders caused by the …